In the United States, 2022 still saw 121 confirmed measles cases across 16 jurisdictions, the highest total since the country declared elimination in 2019. Meanwhile globally measles led to an estimated 128,000 deaths in 2021, with the risk concentrated among children under 5. This post breaks down the timeline from exposure to rash and the outcomes that follow, including complications like pneumonia, encephalitis, and the long tail of SSPE.
Key Takeaways
- Incubation period for measles is 7-21 days, averaging 10-12 days.
- Prodromal phase of measles lasts 2-4 days with fever up to 104°F (40°C).
- Koplik spots appear 1-2 days before rash in 90% of measles cases.
- Pneumonia complicates 5-10% of measles cases, often fatal in children.
- Encephalitis risk 1 per 1,000 cases, mortality 15%.
- SSPE incidence 1 in 1,000-2,000 in developing countries.
- In 2022, the United States reported 121 confirmed measles cases across 16 jurisdictions, the highest since 2019 elimination declaration.
- Globally, measles caused an estimated 128,000 deaths in 2021, mostly among children under 5 years old.
- Measles incidence in the WHO European Region surged to 90,000 cases in 2018 from under 5,000 in 2016.
- Global measles mortality 128,000 in 2021, 95% in low-income countries.
- Case-fatality ratio (CFR) 1-5% in developing countries for children under 5.
- Pre-vaccine era US: 400-500 deaths yearly from 3-4 million cases.
- MMR vaccine contains live attenuated measles virus (Edmonston-Enders strain).
- Two doses of MMR vaccine provide 97% effectiveness against measles.
- First MMR dose at 12-15 months achieves 93% efficacy.
In 2022, measles surged globally and in the US, but strong MMR coverage could prevent most cases.
Related reading
01 · Category
Clinical Aspects26 stats
01
Incubation period for measles is 7-21 days, averaging 10-12 days.
02
Prodromal phase of measles lasts 2-4 days with fever up to 104°F (40°C).
03
Koplik spots appear 1-2 days before rash in 90% of measles cases.
04
Maculopapular rash in measles starts behind ears and spreads cephalocaudally over 3-4 days.
05
Cough, coryza, and conjunctivitis (3 Cs) present in 90% of measles patients.
06
Measles virus transmission occurs via respiratory droplets, infectious 4 days before to 4 days after rash.
07
Secondary attack rate in susceptible household contacts is 85-90%.
08
Virus shedding peaks during prodrome, detectable in urine up to 14 days post-rash.
09
Encephalitis occurs in 1 in 1,000 measles cases, typically 2-6 days after rash.
10
Subacute sclerosing panencephalitis (SSPE) risk is 4-11 per 100,000 cases, latency 7-10 years.
11
Otitis media complicates 7-9% of measles cases in children.
12
Diarrhea affects up to 8% of measles patients, contributing to dehydration.
13
Photophobia and eye pain common due to conjunctivitis in measles prodrome.
14
Leukopenia occurs in 60% of measles cases, with lymphopenia predominant.
15
Elevated transaminases in 50% of measles patients, indicating liver involvement.
16
Thrombocytopenia reported in 15-30% of hospitalized measles cases.
17
Measles rash blanches under pressure, fades in 7 days.
18
Pathognomonic Koplik spots: 1-3mm white on buccal mucosa opposite molars.
19
Fever recurs with rash onset in measles.
20
Virus replicates in respiratory epithelium before viremia day 9-11.
21
Airborne transmission possible up to 2 hours post-patient departure.
22
Diagnosis confirmed by IgM ELISA 72 hours post-rash or PCR.
23
Lymphadenopathy less prominent than in rubella.
24
Splenomegaly in 50% hospitalized measles children.
25
Appendicitis mimic due to mesenteric adenitis in measles.
26
Rash spares palms/soles unlike some exanthems.
Interpretation
Clinical Aspects Interpretation
From a clinical aspects standpoint, measles shows a tight timeline where incubation averages 10 to 12 days and the characteristic 3 Cs appear in 90% of cases, while Koplik spots emerge 1 to 2 days before the rash in 90%, and virus shedding is infectious from 4 days before to 4 days after the rash.
02 · Category
Complications23 stats
01
Pneumonia complicates 5-10% of measles cases, often fatal in children.
02
Encephalitis risk 1 per 1,000 cases, mortality 15%.
03
SSPE incidence 1 in 1,000-2,000 in developing countries.
04
Diarrhea hospitalization rate 8% in measles outbreaks.
05
Blindness from corneal ulceration in 0.1% measles cases in vitamin A deficient areas.
06
Myocarditis rare, <1 per 1,000, but reported in measles.
07
Thrombocytopenia in 1 per 3,000-4,000 cases, self-limiting.
08
Laryngotracheobronchitis in 5% pediatric measles cases.
09
Vitamin A supplementation reduces measles mortality by 50% in deficient children.
10
Hospitalization rate for measles 20-30% in developed countries.
11
Bacterial superinfection causes 60% of measles pneumonia deaths.
12
Degenerative CNS disease (SSPE) fatal in 100%, mean survival 1-2 years post-diagnosis.
13
Acute cerebellar ataxia in 0.02-0.1% measles cases.
14
Acute respiratory distress syndrome (ARDS) in severe measles pneumonia.
15
Hemorrhagic measles rash in 5% vitamin A deficient cases.
16
Guillain-Barré rare post-measles, <1/million.
17
Corneal scarring blindness prevented by vitamin A.
18
Reactive thrombocytosis follows thrombocytopenia recovery.
19
Aseptic meningitis 0.1 per 1,000 measles cases.
20
Secondary bacterial pneumonia: Strep pneumo, H flu common.
21
SSPE earlier onset in <2yo at infection: 4-5 years latency.
22
Orchitis in 30% post-pubertal males with measles.
23
Mastitis in 30% lactating women with measles.
Interpretation
Complications Interpretation
Although most measles cases resolve, the complication risk is substantial because 5 to 10% develop pneumonia and serious neurologic outcomes like encephalitis occur at about 1 in 1,000 with 15% mortality and SSPE affects roughly 1 in 1,000 to 1,000 cases in developing countries.
03 · Category
Epidemiology24 stats
01
In 2022, the United States reported 121 confirmed measles cases across 16 jurisdictions, the highest since 2019 elimination declaration.
02
Globally, measles caused an estimated 128,000 deaths in 2021, mostly among children under 5 years old.
03
Measles incidence in the WHO European Region surged to 90,000 cases in 2018 from under 5,000 in 2016.
04
In 2019, the Democratic Republic of the Congo reported over 250,000 suspected measles cases amid ongoing Ebola response.
05
India's measles cases dropped 80% from 2017 to 2022 due to intensified vaccination campaigns.
06
In 2023, the UK had 1,603 lab-confirmed measles cases, primarily in London.
07
Ethiopia reported 10,559 measles cases in the first half of 2023 across 147 districts.
08
Measles outbreaks in Yemen since 2017 have exceeded 40,000 cases with 700 deaths.
09
In 2022, Nigeria confirmed 3,997 measles cases with 44 deaths in 17 states.
10
Somalia's 2023 measles outbreak reached 11,580 cases and 163 deaths by July.
11
Brazil's measles cases in 2018 totaled 10,322, leading to reintroduction after elimination.
12
In 2021, France reported 101 measles cases, up from 12 in 2020.
13
Pakistan had over 300 measles deaths in 2023, mostly unvaccinated children.
14
The Americas achieved measles elimination in 2016 but saw 23,000 cases in Venezuela by 2019.
15
In 2022, Australia reported 20 measles cases linked to international travel.
16
Madagascar's 2018-2020 measles outbreak recorded 118,000 cases and 1,400 deaths.
17
Measles incidence in unvaccinated US communities reached 1 in 4 infection rate during outbreaks.
18
Globally, 83% of children received first measles vaccine dose in 2022, up from 72% in 2000.
19
In 2016, 1 in 10 US kindergarteners lacked MMR vaccination documentation.
20
Romania reported 14,916 measles cases from 2016-2019 with 64 deaths.
21
In 2023, Ohio US outbreak had 85 cases, 36 hospitalized, all unvaccinated.
22
Measles R0 (basic reproduction number) averages 12-18 in susceptible populations.
23
In 2019, WHO Americas: 8 deaths from Venezuela outbreak.
24
Kenya 2023: 13,500 cases, 170 deaths by September.
Interpretation
Epidemiology Interpretation
Measles epidemiology is showing a clear rebound and geographic spread, with cases rising sharply such as the WHO European Region jumping from under 5,000 in 2016 to 90,000 in 2018 and the US reaching 121 confirmed cases in 2022, even as intensified vaccination in India still helped drive an 80% drop from 2017 to 2022.
More related reading
04 · Category
Mortality And Burden30 stats
01
Global measles mortality 128,000 in 2021, 95% in low-income countries.
02
Case-fatality ratio (CFR) 1-5% in developing countries for children under 5.
03
Pre-vaccine era US: 400-500 deaths yearly from 3-4 million cases.
04
Measles DALYs: 8.7 million globally in 2019 per IHME.
05
Malnutrition increases measles CFR up to 50-fold.
06
2000-2022, vaccination prevented 60% drop in annual deaths from 800k to 128k.
07
In 2019 outbreaks, CFR reached 7.3% in DRC.
08
Economic burden: US outbreak costs $20k-$100k per case in containment.
09
Global under-5 measles deaths: 94% of total in 2021.
10
Pre-vaccine Europe: 2.6 million deaths per year estimated.
11
HIV co-infection raises measles CFR to 11-33%.
12
Vitamin A therapy cuts mortality by 23% overall in trials.
13
Annual global cost of measles control: $1.3 billion needed per GAVI.
14
In Samoa 2019 outbreak, CFR 0.83% with 83 deaths from 5,700 cases.
15
US post-elimination: 1 death in 2015 from 1,282 cases.
16
Projected: without action, 10 million cases, 130k deaths in 2023.
17
In 2022, Europe had 4 deaths from 1,000+ cases.
18
Global economic loss from measles: $10.9 billion 2018-2022.
19
CFR <0.1% in vaccinated populations with access to care.
20
In 2023 first half, 14 African countries reported 7,521 measles deaths.
21
Pre-1963 vaccine: 48,000 hospitalizations yearly US kids.
22
2023 global cases: 10.3 million estimated.
23
Yemen 2017-2023: 45,000 cases, 750 deaths.
24
Cost per averted death: $30via vaccination in Africa.
25
DRC 2019: 250k cases, 6k deaths, CFR 2.4%.
26
Immunodeficiency raises CFR to 30-75%.
27
94% measles deaths in 10 countries 2022.
28
US 1989-1991: 123 deaths from 55k cases.
29
Lifetime SSPE cost: $2.5M per case US.
30
Global 2030 projection: 1.6M deaths without 95% coverage.
Interpretation
Mortality And Burden Interpretation
Mortality and burden from measles remain heavily concentrated in the world’s poorest settings, where deaths reached about 128,000 in 2021 and 95% occurred in low income countries, even though vaccination contributed to a 60% reduction in annual deaths from roughly 800,000 to 128,000 between 2000 and 2022.
05 · Category
Vaccination27 stats
01
MMR vaccine contains live attenuated measles virus (Edmonston-Enders strain).
02
Two doses of MMR vaccine provide 97% effectiveness against measles.
03
First MMR dose at 12-15 months achieves 93% efficacy.
04
Global first-dose measles coverage was 83% in 2022 per WHO/UNICEF estimates.
05
Second-dose coverage lagged at 74% globally in 2022.
06
Herd immunity threshold for measles is 92-95% population immunity.
07
Vaccine-induced immunity lasts decades, with 92% protected 20+ years post-second dose.
08
Adverse events post-MMR: fever in 5-15%, rash in 5% within 7-12 days.
09
Anaphylaxis after MMR occurs in 1.8 per million doses.
10
No link between MMR and autism per 12+ studies involving millions.
11
Measles vaccination averted 56 million deaths globally 2000-2022.
12
Supplemental immunization activities (SIAs) reached 80% coverage in Africa recently.
13
One-dose measles vaccine costs $0.30-$0.50 per child in low-income countries.
14
Thimerosal-free measles vaccines recommended since 1999.
15
Immune-suppressed individuals contraindicated for live MMR vaccine.
16
Pregnancy defer MMR; use immunoglobulin post-exposure if susceptible.
17
MMR first dose protects 93%, second boosts to 97%.
18
Waning immunity rare; revaccination not routinely needed.
19
Outbreak response: single antigen measles vaccine for 6m+ infants.
20
US kindergarten MMR coverage 93.5% in 2022-23.
21
Supplementary campaigns aim for 95% coverage in 80% districts.
22
MR vaccine combo with rubella for gender-neutral delivery.
23
Storage: MMR at 2-8°C, 2-year shelf life.
24
Post-exposure prophylaxis: MMR within 72h, IG within 6 days.
25
IIV contraindicated; use killed vaccine historically risky.
26
Global target: 95% two-dose coverage by 2030.
27
Febrile seizures post-MMR: 1 per 3,000-4,000 doses.
Interpretation
Vaccination Interpretation
With two MMR doses delivering 97% effectiveness against measles, the main vaccination gap is that while first-dose coverage reached 83% globally in 2022, second-dose coverage lagged at 74%, leaving many communities short of the 92 to 95% immunity needed for herd protection.
report visual · Projection
Measles in the spotlight: outbreaks can surge again
After periods of decline, confirmed measles cases rise sharply again in multiple regions—highlighting the need for sustained vaccination coverage.
90,000 Cases
Start
-55.32%
CAGR · 5y
1,603 Cases
Projected
20222027
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Aisha Okonkwo. (2026, February 13). Measles Statistics. Gitnux. https://gitnux.org/measles-statistics
MLA
Aisha Okonkwo. "Measles Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/measles-statistics.
Chicago
Aisha Okonkwo. 2026. "Measles Statistics." Gitnux. https://gitnux.org/measles-statistics.
Sources & references
37 datasets cited across this report · attribution is report-level